Heat transfer in a swirling fluidized bed with Geldart type-D particles

A relatively new variant in fluidized bed technology, designated as the swirling fluidized bed (SFB), was investigated for its heat transfer characteristics when operating with Geldart type D particles. Unlike conventional fluidized beds, the SFB imparts secondary swirling motion to the bed to enhance lateral mixing. Despite its excellent hydrodynamics, its heat transfer characteristics have not been reported in the published literature. Hence, two different sizes of spherical PVC particles (2.61mm and 3.65mm) with the presence of a center body in the bed have been studied at different velocities of the fluidizing gas. The wall-to-bed heat transfer coefficients were measured by affixing a thin constant foil heater on the bed wall. Thermocouples located at different heights on the foil show a decrease in the wall heat transfer coefficient with bed height. It was seen that only a discrete particle model which accounts for the conduction between the particle and the heat transfer surface and the gas-convective augmentation can adequately represent the mechanism of heat transfer in the swirling fluidized bed

Using Role-Play to Enhance Foodborne Illness Crisis Management Capacity in the Produce Industry

Foodborne illness outbreaks have measurable public health effects and often lead to negative produce industry impacts. Reducing loss following a crisis event requires a management plan, although many fresh produce industry members don\u27t have one. Evidence-based workshops using a role-play simulated outbreak were delivered to impact crisis management preparation. A self-reported pre-assessment demonstrated that 21% of participants had a crisis management plan in place prior to attendance, with 79% who employed GAPs. Following the role-play scenario, there was a significant increase in participants\u27 perception of the likelihood of microbial contamination with their product and an increase in crisis planning activities

Commentaire du Comité sur l’asthme de la Société Canadienne de Thoracologie au Sujet de I’utilisation des Bêta-2 agonistes à Longue durée d’action dans le Traitement l’asthme au Canada

Peer Reviewe

Canadian Thoracic Society Asthma Committee Commentary on Long-Acting Beta-2 Agonist Use for Asthma in Canada

Peer Reviewe

Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for children six years of age and over, and adults

BACKGROUND/OBJECTIVE: To integrate new evidence into the Canadian Asthma Management Continuum diagram, encompassing both pediatric and adult asthma

Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for Children Six Years of Age and Over, and Adults

BACKGROUND/OBJECTIVE: To integrate new evidence into the Canadian Asthma Management Continuum diagram, encompassing both pediatric and adult asthma.METHODS: The Canadian Thoracic Society Asthma Committee members, comprised of experts in pediatric and adult respirology, allergy and immunology, emergency medicine, general pediatrics, family medicine, pharmacoepidemiology and evidence-based medicine, updated the continuum diagram, based primarily on the 2008 Global Initiative for Asthma guidelines, and performed a focused review of literature pertaining to key aspects of asthma diagnosis and management in children six years of age and over, and adults.RESULTS: In patients six years of age and over, management of asthma begins with establishing an accurate diagnosis, typically by supplementing medical history with objective measures of lung function. All patients and caregivers should receive self-management education, including a written action plan. Inhaled corticosteroids (ICS) remain the first-line controller therapy for all ages. When asthma is not controlled with a low dose of ICS, the literature supports the addition of long-acting beta2-agonists in adults, while the preferred approach in children is to increase the dose of ICS. Leukotriene receptor antagonists are acceptable as second-line monotherapy and as an alternative add-on therapy in both age groups. Anti-immunoglobulin E therapy may be of benefit in adults, and in children 12 years of age and over with difficult to control allergic asthma, despite high-dose ICS and at least one other controller.CONCLUSIONS: The foundation of asthma management is establishing an accurate diagnosis based on objective measures (eg, spirometry) in individuals six years of age and over. Emphasis is placed on the similarities and differences between pediatric and adult asthma management approaches to achieve asthma control.Peer Reviewe